Lobbying

X-Biotix Therapeutics's latest lobbying report covers Q1 2026, at under $5,000. Its first report covers Q1 2023; the issues it reports most are Budget/Appropriations and Health Issues.

X-Biotix Therapeutics

Latest quarter
No record
Q2 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q2 2026 against the quarter before
First report
Q1 2023
The first quarter a report named it

Lobbying by quarter

X-Biotix Therapeutics lobbying by quarter
X-Biotix Therapeutics lobbying by quarter
QuarterAmountReports
Q1 2023$01
Q2 2023$10K1
Q3 2023$10K1
Q4 2023$10K1
Q1 2024$10K1
Q2 2024$10K1
Q3 2024$10K1
Q4 2024$10K1
Q1 2025$10K1
Q2 2025$01
Q3 2025$01
Q4 2025$01
Q1 2026$01
Q2 2026$00

Policy issues the reports name

  • Budget and appropriations12 reports
  • Health issues7 reports

A report that names several issues counts once for each.

Who was lobbied

  • HOUSE OF REPRESENTATIVES11 reports
  • SENATE9 reports

Firms it paid

Firm
Innovative Federal Strategies$80K13 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
04/20for Q1Innovative Federal StrategiesUnder $5,000
01/20for Q4 2025Innovative Federal StrategiesUnder $5,000
25/10/20for Q3 2025Innovative Federal StrategiesUnder $5,000
25/07/18for Q2 2025Innovative Federal StrategiesUnder $5,000
25/04/16for Q1 2025Innovative Federal Strategies$10K
25/01/20for Q4 2024Innovative Federal Strategies$10K
24/10/21for Q3 2024Innovative Federal Strategies$10K
24/07/21for Q2 2024Innovative Federal Strategies$10K
24/04/22for Q1 2024Innovative Federal Strategies$10K
24/01/21for Q4 2023Innovative Federal Strategies$10K
23/10/20for Q3 2023Innovative Federal Strategies$10K
23/07/20for Q2 2023Innovative Federal Strategies$10K
23/05/30for Q1 2023Innovative Federal StrategiesUnder $5,000
23/05/22for Q1 2023Innovative Federal StrategiesUnder $5,000